Oncternal Therapeutics
Encinitas
About Oncternal Therapeutics
Oncternal Therapeutics is a clinical-stage oncology company developing first-in-class and novel therapies for both rare and common cancers. Their pipeline has recently expanded and now includes two clinical-stage products with common regulatory and development strategies. Oncternal Therapeutics cutting-edge scientific approach is focused on targets that are uniquely expressed within cancer cells, resulting in highly targeted new therapies. They also apply a variety of therapeutic strategies to address different medical challenges - from antibodies and antibody-drug conjugates (ADCs) to small molecules and chimeric antigen receptor T-cells (CAR-T).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $132.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2020)
- Ticker: nasdaq:ONCT
- Website: oncternal.com
- Phone: (858)434-1113
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/oncternal-therapeutics-119298 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.